Tags

Type your tag names separated by a space and hit enter

Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man.
Scand J Gastroenterol. 1990 Jul; 25(7):731-8.SJ

Abstract

The effects of loxiglumide, a potent cholecystokinin (CCK)-receptor antagonist, and atropine, a muscarinic receptor blocker, on exocrine pancreatic secretion stimulated by hormones (secretin plus CCK) and a Lundh test meal were studied in healthy young volunteers. Loxiglumide infused intravenously in gradually increasing doses (2-16 mumol/kg-h) caused a dose-dependent inhibition of pancreatic enzyme secretion induced by intravenous infusion of a constant dose of secretin (82 pmol/kg-h) plus CCK-8 (85 pmol/kg-h) but had relatively smaller influence on duodenal volume flow and bicarbonate output. Atropine (20 nmol/kg) also caused a significant reduction in pancreatic enzyme secretion but failed to affect the volume flow or bicarbonate secretion induced by secretin plus CCK, possibly owing to the high doses of secretin and CCK used in these tests. Both loxiglumide and atropine inhibited the pancreatic enzyme response to a Lundh meal, but atropine was more effective in the early phase and loxiglumide in the late phase of the postprandial secretion. Neither loxiglumide nor atropine affected the plasma gastrin and CCK levels, but both antagonists reduced plasma pancreatic polypeptide responses to the Lundh meal. We conclude that 1) loxiglumide results in a relatively stronger suppression of the pancreatic enzyme than aqueous-alkaline secretion induced by secretin plus CCK, whereas atropine inhibits only enzyme secretion; and 2) both loxiglumide and atropine suppress the pancreatic enzyme responses to the meal stimulation without affecting the postprandial plasma gastrin and CCK responses.

Authors+Show Affiliations

Gastroenterological Clinic, Academy of Medicine, Bialystok, Poland.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

2396088

Citation

Gabryelewicz, A, et al. "Comparison of Loxiglumide, a Cholecystokinin Receptor Antagonist, and Atropine On Hormonal and Meal-stimulated Pancreatic Secretion in Man." Scandinavian Journal of Gastroenterology, vol. 25, no. 7, 1990, pp. 731-8.
Gabryelewicz A, Kulesza E, Konturek SJ. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man. Scand J Gastroenterol. 1990;25(7):731-8.
Gabryelewicz, A., Kulesza, E., & Konturek, S. J. (1990). Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man. Scandinavian Journal of Gastroenterology, 25(7), 731-8.
Gabryelewicz A, Kulesza E, Konturek SJ. Comparison of Loxiglumide, a Cholecystokinin Receptor Antagonist, and Atropine On Hormonal and Meal-stimulated Pancreatic Secretion in Man. Scand J Gastroenterol. 1990;25(7):731-8. PubMed PMID: 2396088.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man. AU - Gabryelewicz,A, AU - Kulesza,E, AU - Konturek,S J, PY - 1990/7/1/pubmed PY - 1990/7/1/medline PY - 1990/7/1/entrez SP - 731 EP - 8 JF - Scandinavian journal of gastroenterology JO - Scand J Gastroenterol VL - 25 IS - 7 N2 - The effects of loxiglumide, a potent cholecystokinin (CCK)-receptor antagonist, and atropine, a muscarinic receptor blocker, on exocrine pancreatic secretion stimulated by hormones (secretin plus CCK) and a Lundh test meal were studied in healthy young volunteers. Loxiglumide infused intravenously in gradually increasing doses (2-16 mumol/kg-h) caused a dose-dependent inhibition of pancreatic enzyme secretion induced by intravenous infusion of a constant dose of secretin (82 pmol/kg-h) plus CCK-8 (85 pmol/kg-h) but had relatively smaller influence on duodenal volume flow and bicarbonate output. Atropine (20 nmol/kg) also caused a significant reduction in pancreatic enzyme secretion but failed to affect the volume flow or bicarbonate secretion induced by secretin plus CCK, possibly owing to the high doses of secretin and CCK used in these tests. Both loxiglumide and atropine inhibited the pancreatic enzyme response to a Lundh meal, but atropine was more effective in the early phase and loxiglumide in the late phase of the postprandial secretion. Neither loxiglumide nor atropine affected the plasma gastrin and CCK levels, but both antagonists reduced plasma pancreatic polypeptide responses to the Lundh meal. We conclude that 1) loxiglumide results in a relatively stronger suppression of the pancreatic enzyme than aqueous-alkaline secretion induced by secretin plus CCK, whereas atropine inhibits only enzyme secretion; and 2) both loxiglumide and atropine suppress the pancreatic enzyme responses to the meal stimulation without affecting the postprandial plasma gastrin and CCK responses. SN - 0036-5521 UR - https://www.unboundmedicine.com/medline/citation/2396088/Comparison_of_loxiglumide_a_cholecystokinin_receptor_antagonist_and_atropine_on_hormonal_and_meal_stimulated_pancreatic_secretion_in_man_ L2 - https://www.tandfonline.com/doi/full/10.3109/00365529008997600 DB - PRIME DP - Unbound Medicine ER -